Evidence map›Paper›PMID 42282006›Full record

ArticleResearch square2026

Orally bioavailable CB

Slava Rom, Viviana Zuluaga-Ramirez, Sachin Gaghate, Uwe Grether, Wolfgang Guba, Nancy L Reichenbach, Mario Van der Stelt, Christoph Ullmer, Pal Pacher, Yuri Persidsky

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Slava RomTemple University.
Viviana Zuluaga-RamirezTemple University.
Sachin GaghateTemple University.
Uwe GretherRoche (Switzerland).
Wolfgang GubaRoche (Switzerland).
Nancy L ReichenbachTemple University.
Mario Van der SteltLeiden University.
Christoph UllmerRoche (Switzerland).
Pal PacherNational Institute on Alcohol Abuse and Alcoholism.
Yuri PersidskyTemple University.

Funding

BBB Tight Junctions During HIV-1 dementiaR01MH065151 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PERSIDSKY, YURI · 2002 to 2016
$5.9M
CNS injury caused by HIV-1 and alcohol: Protective effects of CB2 activationR37AA015913 · NIAAA · TEMPLE UNIV OF THE COMMONWEALTH · PI PERSIDSKY, YURI · 2010 to 2019
$3.6M
Novel CB2 agonists shield brain from HIV infection and alcohol exposureU01AA023552 · NIAAA · TEMPLE UNIV OF THE COMMONWEALTH · PI PERSIDSKY, YURI · 2016 to 2020
$1.8M
Protective role of let-7 microRNAs in brain endothelial dysfunction during ischemia/reperfusion injuryR01NS101135 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI ROM, SLAVA · 2018 to 2022
$1.7M
PPAR-gamma-mediated neuroprotection against HIV-1 and alcohol CNS injuryR01AA015913 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PERSIDSKY, YURI · 2005 to 2009
$1.6M
NIAAA NIH HHS R01 AA015913NIAAA NIH HHS R37 AA015913NIAAA NIH HHS U01 AA023552NIMH NIH HHS R01 MH065151NINDS NIH HHS R01 NS101135
6 · The paper itself

Abstract

Background: Neuroinflammation and blood-brain barrier (BBB) dysfunction are key contributors to the pathogenesis of many neurological disorders. Cannabinoid receptor 2 (CB Methods: Novel CB Results: Among the compounds tested, RO6839828 and HU-910 demonstrated the greatest efficacy in reducing leukocyte adhesion to and migration across the BBB. CB Conclusions: Novel orally bioavailable CB

Indexed as

BBBCB2 receptor agonistsleukocyte–endothelial interactionsneuroinflammation

Identifiers

PMID42282006
PMCPMC13252526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.